Business
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President,
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.\n\n\n“We are pleased to announce Kevin’s appointment to lead our business development and partnering activities,” said Steve Davis, Acadia’s President and Chief Executive Officer. “Our recent successful launch of DAYBUE™ (trofinetide), the first and only drug approved for the treatment of Rett syndrome, together with the continued success of NUPLAZID® (pimavanserin), the first and only drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, positions us to build on our first-to-market expertise as we further expand our franchises in rare disease and neuropsychiatry.”\n\n\nDr. Oliver brings more than three decades of biopharmaceutical research and development and business development experience to Acadia. Before joining Acadia, Dr. Oliver served as SVP, Head of Global Business Development & Licensing and Alliance Management, as well as Chief Operations Officer, U.S. and Europe at Simcere Pharmaceutical Group. Prior to Simcere, Dr. Oliver held various key positions at Merck, where he served for over 20 years in research and development and business development leadership roles, and at Alcon as Head of Business Development, Global External Alliances.\n\n\n“I am excited to join Acadia at such a pivotal time as we execute on our company’s strategy to grow our portfolio of central nervous system assets,” said Dr. Oliver. “The recent success of DAYBUE, originally partnered for North America in 2018, together with the recent expansion of this partnership to acquire global rights, underscores Acadia’s commitment to being the partner of choice in breakthrough therapies to treat central nervous system disorders.”\n\n\nDr. Oliver obtained his bachelor's degree in Immunology from King's College London and holds a Ph.D. in Pathology from the University of Cambridge.\n\n\nAbout NUPLAZID® (pimavanserin)\n\n\nPimavanserin is a selective serotonin inverse agonist and antagonist preferen...